Shares of biotechnology company AnPac Bio-Medical Science Co., Ltd. (ANPC) are surging more than 90% Wednesday morning after the company reported strong demand for its cancer screening tests and set a record in paid test volume in the third quarter.
For FY20, the company sees revenue growth of 100% to $3 million to $3.3 million. Average selling price (ASP) of its cancer screening test in 2020 is expected to increase year-over-year contributing to a higher revenue growth forecast.
The Company plans to release its full year results in early March 2021.
ANPC is currently trading at $6.77. It has traded in the range of $3.15- $12.18 in the past 52 weeks.
For comments and feedback contact: editorial@rttnews.com